Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia [artículo]
Por: Ayala Díaz, Rosa María [Hematología y Hemoterapia]
| Barrio García, Santiago [Hematología y Hemoterapia] | Jiménez Ubieto, Ana Isabel [Hematología y Hemoterapia] | Martínez López, Joaquín [Hematología y Hemoterapia] | Rapado Martínez, Inmaculada [Instituto de Investigación i+12] | Rueda Fernández, Daniel [Hematología y Hemoterapia].
Colaborador(es): Servicio de Hematología y Hemoterapia | Instituto de Investigación imas12.
Editor: Annals of Hematology, 2011Descripción: 90(8):939-946.Recursos en línea: Solicitar documento Resumen: This study investigates the differential gene expression profile of JAK2(V617F)-positive myeloproliferative neoplasm (MPN) patients, with and without response to hydroxyurea (HU) treatment. Twenty-one polycythemia vera, 28 essential thrombocythemia, eight secondary erythrocytosis, and 30 controls were studied. Thirty-four genes were overexpressed in patients who did not respond to HU. Of these, some participate in proliferative pathways: MAPK, AKT, Src kinase (SFK), and JAK2 pathway. JAK2 allele burden was similar between groups of responders and nonresponder. A molecular fingerprint distinguishes JAK2(V617F)-positive MPN patients without response to HU treatment, with overexpression of JAK2, MAPK14, PIK3CA, and SFK genes.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC472 (Navegar estantería) | Disponible |
Formato Vancouver:
Albizua E, Gallardo M, Barrio S, Rapado I, Jiménez A, Ayala R, et al. Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia. Ann Hematol. 2011;90(8):939-46.
PMID: 21331593
Contiene 26 referencias.
This study investigates the differential gene expression profile of JAK2(V617F)-positive myeloproliferative neoplasm (MPN) patients, with and without response to hydroxyurea (HU) treatment. Twenty-one polycythemia vera, 28 essential thrombocythemia, eight secondary erythrocytosis, and 30 controls were studied. Thirty-four genes were overexpressed in patients who did not respond to HU. Of these, some participate in proliferative pathways: MAPK, AKT, Src kinase (SFK), and JAK2 pathway. JAK2 allele burden was similar between groups of responders and nonresponder. A molecular fingerprint distinguishes JAK2(V617F)-positive MPN patients without response to HU treatment, with overexpression of JAK2, MAPK14, PIK3CA, and SFK genes.
No hay comentarios para este ejemplar.